

AMENDMENTS TO THE SPECIFICATION

On page 1, after the title, please amend the cross-referencing paragraph as follows:

CROSS REFERENCE TO RELATED APPLICATIONS

This application is the United States national stage filing of corresponding international application number PCT/US2004/042710 filed December 20, 2004, which claims the benefit of and priority to U.S. Provisional Application No. 60/532,842, filed December 23, 2003, ~~hereby incorporated by reference in its entirety~~ all of which are hereby incorporated by reference in their entirety.

On page 18, please amend the paragraph at lines 16-23 as follows:

Other useful targeting moieties include analogs of somatostatin, which, for example, are Lanreotide (Nal-Cys-Thr-DTrp-Lys-Val-Cys-Thr-NH₂) (SEQ ID NO: 1), Octreotide (Nal-Cys-Thr-DTrp-Lys-Val-Cys-Thr-ol) (SEQ ID NO: 2), and Y³-Octreotate (DPhe-Cys-Tyr-DTrp-Lys-Thr-Cys-Thr-OH) (SEQ ID NO: 3). These analogs are described in the literature (*e.g.*, Potent Somatostatin Analogs Containing N-terminal Modifications, S. H. Kim, J. Z. Dong, T. D. Gordon, H. L. Kimball, S. C. Moreau, J.-P. Moreau, B.A. Morgan, W. A. Murphy and J. E. Taylor; Peptides: Chemistry, Structure and Biology Pravin T. P. Kaumaya, and Roberts S. Hodges (Eds)., Mayflower Scientific LTD., 1996, pgs 241-243.)

On pages 20-21, please amend the bridging paragraph at line 21 as follows:

In an exemplary embodiment, the targeting peptide Q is LHRH or an analog or derivative thereof. For example, it is well known in the art that position 6 of LHRH agonists may be substituted with different functional groups, such as, for example D-

Lysine. In a preferred embodiment, the targeting peptide Q is an LHRH analog of the formula PGlu-His-Trp-**W**-Tyr-DLys-**X**-**Y**-Pro-**Z** (SEQ ID NO: 4), wherein

W = Ser, NMeSer, or Thr.

X = Leu, NMeLeu, t-ButylGly.

Y = Arg, Arg(Et₂), Cit, Lys(isopropyl).

Z = Gly-NH₂, NHEthyl, Azagly-NH₂.

Linkers of the invention coupled to glycine and D-Lysine can be attached to the LHRH analog at position 6.